Clinical Trials – Fragile X Syndrome Clinic

Acamprosate Fragile X Syndrome (Ages 5-22)

Study of acamprosate in youth with fragile X syndrome versus placebo

Expressive Language Sampling as an Outcome Measure

Expressive language sampling as an outcome measure

Fragile X Investigational Drug Study (Adult)

An open-label study to evaluate the long-term safety and efficacy of an investigational drug in adults with fragile X syndrome

Fragile X Study: Premutation Carriers

Neurological phenotype in FMR1 premutation carriers

Fragile X Syndrome Treatment with MC01CI Study

A six-week, randomized, multicenter, double-blind, parallel, flexed- and fixed-dose study of MC01CI (Metadoxine Extended-Release) 700 mg and 1400 mg compared with placebo in adults and adolescents with fragile X syndrome

Fragile X Syndrome Treatment With NNZ-2566 Compared to Placebo

Study of drug NNZ-2566 in fragile X syndrome compared to placebo